Protagonist Therapeutics Inc (PTGX, Financial) has reported an insider sell by President and CEO PATEL DINESH V PH D, according to a recent SEC filing. On March 1, 2024, the insider sold 30,000 shares of the company at an undisclosed price.
Over the past year, PATEL DINESH V PH D has sold a total of 105,000 shares and has not made any purchases of the company's stock. This latest transaction continues a trend of insider sales at Protagonist Therapeutics Inc, with a total of 6 insider sells and no insider buys reported over the same period.
Protagonist Therapeutics Inc is a biopharmaceutical company focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company's pipeline includes drug candidates that are designed to target iron homeostasis, inflammation, and cancer.
The insider transaction history suggests a pattern of insider sales over the past year. This information can be relevant to shareholders and potential investors as they assess the company's stock performance and insider confidence.
On the valuation front, shares of Protagonist Therapeutics Inc were trading at $31.62 on the day of the insider's recent sale, giving the company a market capitalization of $1.852 billion. The stock's price-to-GF-Value ratio stands at 0.8, indicating that the stock is modestly undervalued based on its GF Value of $39.52.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
Given the current market cap and the GF Value, investors may consider the stock's valuation in their investment decisions, alongside the recent insider selling activity.
Please note that the information provided in this article is based on the latest available data and SEC filings and does not constitute investment advice.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
